About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: PBYI
- Previous Close: $36.20
- 50 Day Moving Average: $34.74
- 200 Day Moving Average: $45.09
- 52-Week Range: $36,818,000.00 - $19.74
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.04
- P/E Growth: 0.11
- Market Cap: $1.33B
- Outstanding Shares: 36,818,000
- Beta: 0.35
- Return on Equity: -179.99%
- Return on Assets: -141.40%
Companies Related to Puma Biotechnology:
- Current Ratio: 3.12%
- Quick Ratio: 3.12%
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."
Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?
7 equities research analysts have issued 12 month price targets for Puma Biotechnology's shares. Their predictions range from $36.00 to $111.00. On average, they expect Puma Biotechnology's stock price to reach $76.33 in the next twelve months.
When will Puma Biotechnology announce their earnings?
Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Puma Biotechnology stock?
Puma Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (9.40%), Orbimed Advisors LLC (6.18%), Janus Capital Management LLC (6.01%), State Street Corp (5.29%), Tourbillon Capital Partners L.P. (1.22%) and Teachers Retirement System of The State of Kentucky (0.17%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Richard Paul Bryce and Robert Charnas.
Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?
Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Janus Capital Management LLC, Oxford Asset Management, Federated Investors Inc. PA, State Board of Administration of Florida Retirement System and Putnam Investments LLC. Company insiders that have sold Puma Biotechnology stock in the last year include Alan H Auerbach, Richard Paul Bryce and Robert Charnas.
Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?
Puma Biotechnology's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Tourbillon Capital Partners L.P., Teachers Retirement System of The State of Kentucky, Numeric Investors LLC, Highland Capital Management LP, Paulson & CO. Inc., A.R.T. Advisors LLC and Perceptive Advisors LLC.
How do I buy Puma Biotechnology stock?
Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Puma Biotechnology stock cost?
One share of Puma Biotechnology stock can currently be purchased for approximately $36.20.